The U.S. Food and Drug Administration (FDA) has approved prademagene zamikeracel (Zevaskyn) for the treatment of blistering ...

The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

(NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in adults and children with recessive dystrophic ...

Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

The U.S. Food and Drug Administration has approved Zevaskyn (prademagene zamikeracel) for patients with the rare, genetic ...

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...

The FDA approved Abeona’s Zevaskyn™ (prademagene zamikeracel) as the first (and so far only) cell-based gene therapy to be authorized for recessive dystrophic epidermolysis bullosa (RDEB), a ...

Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Tuesday, April 29, that it has received U.S. Food and Drug ...

The U.S. Food and Drug Administration has approved Zevaskyn for patients suffering from rare, genetic skin disease recessive ...